ATTENTION Viking Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your RightsAccesswire • 11/06/24
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High ExpectationsSeeking Alpha • 11/04/24
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And SafetyBenzinga • 11/04/24
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectationsReuters • 11/04/24
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024PRNewsWire • 11/04/24
Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug DataInvestors Business Daily • 11/04/24
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024PRNewsWire • 10/28/24
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?The Motley Fool • 10/27/24
S&P 500, Nasdaq rise sharply ending 3-day losing streak; Viking Therapeutics surge, while Capri's shares slumpInvezz • 10/25/24
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline AdvancementsZacks Investment Research • 10/24/24